Valuation: Winston Pharmaceuticals, Inc.

Market Cap 15.48M 13.6M 12.65M 11.6M 21.8M 1.49B 22.14M 150M 58.67M 733M 58.12M 56.87M 2.53B P/E 2008
-49.9x
P/E 2009 -6.46x
Enterprise Value 13.92M 12.22M 11.37M 10.43M 19.6M 1.34B 19.9M 135M 52.74M 659M 52.25M 51.13M 2.28B EV / Sales 2008
572x
EV / Sales 2009 14.4x
Free-Float
100%
Yield 2008 *
-
Yield 2009 -
Manager TitleAgeSince
Chief Executive Officer 83 2010-02-18
Change 5-day change 1-year change 3-year change Capi.($)
-39.14%-.--% - - 77
+0.86%+1.43%+47.17%+161.40% 1,067B
+1.59%+4.09%+56.51%+52.79% 635B
+0.95%+1.91%+36.30%+83.13% 458B
+1.60%+6.25%+37.00%+30.00% 347B
-0.60%+1.52%+36.67%+39.80% 295B
-0.14%+0.60%+17.29%+18.19% 262B
+0.09%-2.82%-29.09%-41.29% 216B
+1.22%+2.66%+22.66%+59.81% 203B
-1.18%-3.70%+11.28%+67.43% 161B
Average -3.47%+1.33%+26.20%+52.36% 404.78B
Weighted average by Cap. +0.76%+1.95%+35.99%+78.15%

Financials

2008 2009
Net sales 453K 397K 370K 339K 637K 43.58M 647K 4.39M 1.71M 21.43M 1.7M 1.66M 74.08M 1.39M 1.22M 1.14M 1.05M 1.96M 134M 1.99M 13.53M 5.28M 66.03M 5.24M 5.12M 228M
Net income -5.14M -4.52M -4.2M -3.85M -7.24M -495M -7.35M -49.87M -19.48M -243M -19.3M -18.89M -842M -2.66M -2.33M -2.17M -1.99M -3.74M -256M -3.8M -25.75M -10.06M -126M -9.97M -9.75M -435M
Net Debt -5.63M -4.94M -4.6M -4.22M -7.92M -542M -8.05M -54.58M -21.32M -266M -21.12M -20.67M -921M -1.56M -1.37M -1.28M -1.17M -2.2M -151M -2.23M -15.16M -5.92M -73.99M -5.87M -5.74M -256M
Logo Winston Pharmaceuticals, Inc.
Winston Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company discovers, develops and commercializes therapeutics for managing and alleviating pain. The Company's late stage candidates include products for the treatment of episodic cluster headache, chronic migraine headache, osteoarthritis, rheumatoid arthritis, neuropathic pain, and pain and inflammation in inflammatory bowel disease. The Company is developing Civamide, which is a transient receptor potential channels vanilloid-1 (TRPV-1) modulator in different dosage forms for several different pain indications. The Company's other products are under development for the treatment of headache and neuropathic and rheumatological pain.
Employees
-